| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiopancreatography, Endoscopic Retrograde | 20 | 2022 | 348 | 4.730 |
Why?
|
| Pancreatitis | 21 | 2021 | 279 | 4.440 |
Why?
|
| Pancreatitis, Chronic | 19 | 2022 | 168 | 3.550 |
Why?
|
| Endosonography | 13 | 2021 | 177 | 1.620 |
Why?
|
| Pancreatic Neoplasms | 7 | 2017 | 332 | 1.420 |
Why?
|
| Pancreas | 8 | 2022 | 225 | 1.370 |
Why?
|
| Sphincter of Oddi | 2 | 2021 | 51 | 1.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2017 | 46 | 1.220 |
Why?
|
| Osteosarcoma | 9 | 2019 | 35 | 1.130 |
Why?
|
| Sphincterotomy, Endoscopic | 4 | 2022 | 79 | 1.120 |
Why?
|
| MicroRNAs | 6 | 2019 | 447 | 1.100 |
Why?
|
| Biomarkers, Tumor | 6 | 2019 | 508 | 1.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 756 | 0.920 |
Why?
|
| Bone Neoplasms | 7 | 2019 | 100 | 0.910 |
Why?
|
| Sphincterotomy | 1 | 2022 | 2 | 0.870 |
Why?
|
| Acute Disease | 10 | 2022 | 658 | 0.790 |
Why?
|
| Bile Ducts | 1 | 2022 | 59 | 0.780 |
Why?
|
| Endoscopy, Digestive System | 2 | 2021 | 78 | 0.780 |
Why?
|
| Humans | 94 | 2022 | 68618 | 0.730 |
Why?
|
| Clinical Competence | 5 | 2020 | 657 | 0.710 |
Why?
|
| Pancreatic Diseases | 5 | 2022 | 66 | 0.640 |
Why?
|
| Middle Aged | 51 | 2021 | 21147 | 0.620 |
Why?
|
| Decision Support Techniques | 2 | 2020 | 191 | 0.610 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 123 | 0.590 |
Why?
|
| Credentialing | 1 | 2017 | 23 | 0.580 |
Why?
|
| Gastroenterologists | 1 | 2017 | 11 | 0.580 |
Why?
|
| Endoscopy, Gastrointestinal | 6 | 2019 | 171 | 0.570 |
Why?
|
| Male | 60 | 2021 | 37321 | 0.540 |
Why?
|
| Gastroenterology | 4 | 2019 | 98 | 0.530 |
Why?
|
| Female | 59 | 2021 | 38074 | 0.530 |
Why?
|
| Hospitals | 1 | 2017 | 265 | 0.480 |
Why?
|
| Patient Admission | 1 | 2015 | 99 | 0.480 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 4 | 2014 | 20 | 0.470 |
Why?
|
| Risk Factors | 17 | 2021 | 5731 | 0.460 |
Why?
|
| Aged | 35 | 2021 | 14862 | 0.450 |
Why?
|
| Ambulatory Care | 1 | 2015 | 340 | 0.430 |
Why?
|
| Prospective Studies | 21 | 2021 | 3705 | 0.430 |
Why?
|
| Adult | 38 | 2021 | 21403 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2016 | 446 | 0.390 |
Why?
|
| Indomethacin | 3 | 2019 | 107 | 0.390 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2013 | 239 | 0.380 |
Why?
|
| Retrospective Studies | 17 | 2021 | 7277 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 332 | 0.370 |
Why?
|
| Drug Resistance, Multiple | 3 | 2016 | 56 | 0.370 |
Why?
|
| Secretin | 3 | 2014 | 18 | 0.360 |
Why?
|
| Abdominal Pain | 4 | 2022 | 97 | 0.360 |
Why?
|
| Recurrence | 4 | 2022 | 948 | 0.340 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2019 | 240 | 0.340 |
Why?
|
| Smoking | 7 | 2021 | 1452 | 0.320 |
Why?
|
| Hypertriglyceridemia | 2 | 2020 | 21 | 0.310 |
Why?
|
| Gastric Bypass | 2 | 2021 | 83 | 0.310 |
Why?
|
| Pancreatic Ducts | 3 | 2018 | 76 | 0.300 |
Why?
|
| Biliary Tract Diseases | 2 | 2020 | 50 | 0.290 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 1851 | 0.290 |
Why?
|
| United States | 12 | 2022 | 7367 | 0.280 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 1085 | 0.270 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2018 | 16 | 0.260 |
Why?
|
| Alcohol Drinking | 7 | 2021 | 805 | 0.260 |
Why?
|
| Liposarcoma | 2 | 2016 | 13 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 2 | 2017 | 107 | 0.250 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2017 | 60 | 0.250 |
Why?
|
| Choledocholithiasis | 2 | 2014 | 14 | 0.240 |
Why?
|
| Cholangiography | 2 | 2014 | 55 | 0.240 |
Why?
|
| Bariatric Surgery | 2 | 2019 | 90 | 0.240 |
Why?
|
| Quinolines | 2 | 2015 | 48 | 0.240 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2014 | 59 | 0.240 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 800 | 0.230 |
Why?
|
| Piperidines | 2 | 2015 | 123 | 0.230 |
Why?
|
| Pyrimidines | 2 | 2016 | 178 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 475 | 0.230 |
Why?
|
| Young Adult | 14 | 2020 | 5717 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2019 | 2800 | 0.220 |
Why?
|
| Image Enhancement | 2 | 2014 | 143 | 0.220 |
Why?
|
| Demography | 3 | 2019 | 279 | 0.220 |
Why?
|
| Aged, 80 and over | 11 | 2018 | 4848 | 0.210 |
Why?
|
| Infection Control | 2 | 2020 | 101 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 331 | 0.210 |
Why?
|
| Paclitaxel | 4 | 2016 | 140 | 0.210 |
Why?
|
| Cholangiocarcinoma | 2 | 2013 | 20 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 186 | 0.210 |
Why?
|
| Bile Duct Neoplasms | 2 | 2013 | 39 | 0.200 |
Why?
|
| Cell Line, Tumor | 9 | 2017 | 1851 | 0.200 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 28 | 0.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2017 | 468 | 0.200 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 1753 | 0.200 |
Why?
|
| Quality of Life | 3 | 2022 | 1515 | 0.200 |
Why?
|
| Sarcoma | 1 | 2022 | 70 | 0.200 |
Why?
|
| Pain | 2 | 2015 | 472 | 0.200 |
Why?
|
| Food Intolerance | 1 | 2021 | 1 | 0.190 |
Why?
|
| Sarcoma, Synovial | 1 | 2020 | 11 | 0.190 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2021 | 11 | 0.190 |
Why?
|
| Multiple Organ Failure | 1 | 2021 | 36 | 0.190 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2020 | 23 | 0.190 |
Why?
|
| Duodenoscopes | 1 | 2020 | 7 | 0.190 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 694 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 931 | 0.180 |
Why?
|
| Chromatin | 1 | 2020 | 76 | 0.180 |
Why?
|
| Equipment Contamination | 1 | 2020 | 38 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 168 | 0.180 |
Why?
|
| Carcinoma | 1 | 2022 | 215 | 0.180 |
Why?
|
| Eating | 1 | 2021 | 119 | 0.180 |
Why?
|
| Stents | 4 | 2021 | 657 | 0.180 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 201 | 0.180 |
Why?
|
| Learning Curve | 2 | 2017 | 20 | 0.180 |
Why?
|
| Prognosis | 7 | 2020 | 2093 | 0.180 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2017 | 6 | 0.180 |
Why?
|
| Child | 10 | 2022 | 6405 | 0.180 |
Why?
|
| Manometry | 1 | 2021 | 276 | 0.170 |
Why?
|
| Fractures, Spontaneous | 1 | 2019 | 7 | 0.170 |
Why?
|
| Anastomotic Leak | 1 | 2019 | 11 | 0.170 |
Why?
|
| Gastrectomy | 1 | 2019 | 24 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 163 | 0.170 |
Why?
|
| Reproducibility of Results | 7 | 2020 | 2077 | 0.160 |
Why?
|
| Cohort Studies | 7 | 2021 | 2358 | 0.160 |
Why?
|
| Tobacco Smoking | 1 | 2019 | 41 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.160 |
Why?
|
| Chordoma | 2 | 2015 | 9 | 0.160 |
Why?
|
| Societies, Medical | 2 | 2018 | 403 | 0.160 |
Why?
|
| Contrast Media | 4 | 2014 | 595 | 0.160 |
Why?
|
| ROC Curve | 4 | 2021 | 392 | 0.160 |
Why?
|
| Reference Standards | 1 | 2018 | 115 | 0.150 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 75 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1553 | 0.150 |
Why?
|
| Adolescent | 10 | 2019 | 8912 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2017 | 714 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2018 | 112 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2017 | 16 | 0.150 |
Why?
|
| Genomic Imprinting | 1 | 2017 | 10 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.150 |
Why?
|
| Sick Leave | 1 | 2017 | 6 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.140 |
Why?
|
| Unemployment | 1 | 2017 | 18 | 0.140 |
Why?
|
| RNA, Neoplasm | 1 | 2017 | 76 | 0.140 |
Why?
|
| Sex Factors | 5 | 2021 | 1266 | 0.140 |
Why?
|
| Gene Targeting | 1 | 2017 | 58 | 0.140 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 41 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 34 | 0.140 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2016 | 1 | 0.140 |
Why?
|
| Obesity | 3 | 2017 | 1076 | 0.140 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2016 | 12 | 0.140 |
Why?
|
| Pancreatitis, Alcoholic | 1 | 2016 | 11 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2013 | 14 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.140 |
Why?
|
| Common Bile Duct Diseases | 1 | 2016 | 24 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 87 | 0.140 |
Why?
|
| Cholelithiasis | 1 | 2016 | 66 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 627 | 0.140 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 1140 | 0.130 |
Why?
|
| Research Support as Topic | 1 | 2016 | 58 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 772 | 0.130 |
Why?
|
| Benzylidene Compounds | 1 | 2015 | 16 | 0.130 |
Why?
|
| Nuclear Proteins | 2 | 2022 | 271 | 0.130 |
Why?
|
| Biomarkers | 2 | 2018 | 1593 | 0.130 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 77 | 0.130 |
Why?
|
| Indiana | 1 | 2015 | 35 | 0.130 |
Why?
|
| Pancreatectomy | 2 | 2013 | 129 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 3259 | 0.130 |
Why?
|
| Physicians | 1 | 2019 | 324 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 30 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2020 | 1342 | 0.120 |
Why?
|
| Aptitude | 1 | 2014 | 5 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2015 | 87 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2015 | 26 | 0.120 |
Why?
|
| Hospitals, University | 1 | 2015 | 169 | 0.120 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2014 | 5 | 0.120 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 86 | 0.120 |
Why?
|
| Esophageal Perforation | 1 | 2014 | 13 | 0.120 |
Why?
|
| Bile | 1 | 2014 | 35 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 91 | 0.120 |
Why?
|
| Acinar Cells | 1 | 2014 | 8 | 0.120 |
Why?
|
| Bicarbonates | 1 | 2014 | 21 | 0.120 |
Why?
|
| Analgesics | 1 | 2015 | 118 | 0.120 |
Why?
|
| Cell Membrane Permeability | 1 | 2014 | 59 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2016 | 237 | 0.120 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 51 | 0.120 |
Why?
|
| Prevalence | 4 | 2021 | 1619 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 183 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 28 | 0.110 |
Why?
|
| Meglumine | 1 | 2013 | 16 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2010 | 76 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2020 | 2279 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2020 | 2007 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2014 | 190 | 0.110 |
Why?
|
| Hospitalization | 4 | 2021 | 978 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 267 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2019 | 7029 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 767 | 0.110 |
Why?
|
| Organometallic Compounds | 1 | 2013 | 95 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 310 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1174 | 0.100 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2013 | 101 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 1030 | 0.100 |
Why?
|
| Administration, Rectal | 3 | 2019 | 26 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 498 | 0.100 |
Why?
|
| Digestive System Diseases | 1 | 2011 | 16 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1465 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2013 | 275 | 0.100 |
Why?
|
| Propofol | 1 | 2011 | 36 | 0.100 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2011 | 43 | 0.100 |
Why?
|
| Conscious Sedation | 1 | 2011 | 61 | 0.100 |
Why?
|
| Hypotension | 1 | 2011 | 74 | 0.100 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2011 | 67 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 34 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 6 | 0.090 |
Why?
|
| Leiomyoma | 1 | 2010 | 28 | 0.090 |
Why?
|
| Tissue Array Analysis | 3 | 2016 | 53 | 0.090 |
Why?
|
| Hypoxia | 1 | 2011 | 169 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 108 | 0.090 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2010 | 40 | 0.090 |
Why?
|
| Length of Stay | 3 | 2021 | 780 | 0.090 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 283 | 0.090 |
Why?
|
| Age Factors | 3 | 2021 | 1864 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 194 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2011 | 202 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2010 | 119 | 0.090 |
Why?
|
| Drug Synergism | 3 | 2015 | 260 | 0.090 |
Why?
|
| North America | 2 | 2020 | 112 | 0.080 |
Why?
|
| Body Mass Index | 3 | 2020 | 867 | 0.080 |
Why?
|
| Doxorubicin | 3 | 2016 | 231 | 0.080 |
Why?
|
| Weight Loss | 1 | 2011 | 319 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 504 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 1330 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2016 | 1615 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2011 | 219 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2016 | 125 | 0.080 |
Why?
|
| Triglycerides | 2 | 2020 | 184 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 371 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1046 | 0.070 |
Why?
|
| Registries | 2 | 2021 | 733 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2001 | 178 | 0.070 |
Why?
|
| Disease Progression | 2 | 2021 | 1038 | 0.070 |
Why?
|
| Coronary Disease | 2 | 2001 | 358 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2017 | 328 | 0.060 |
Why?
|
| Genotype | 2 | 2019 | 786 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 1056 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 852 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 1603 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 88 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 304 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2019 | 1738 | 0.060 |
Why?
|
| Comorbidity | 2 | 2019 | 1426 | 0.060 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2022 | 4 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 18 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 24 | 0.050 |
Why?
|
| Carcinoma, Medullary | 2 | 1999 | 7 | 0.050 |
Why?
|
| Cell Survival | 2 | 2016 | 901 | 0.050 |
Why?
|
| Morphine Derivatives | 1 | 2021 | 2 | 0.050 |
Why?
|
| Hematocrit | 1 | 2021 | 70 | 0.050 |
Why?
|
| Blood Urea Nitrogen | 1 | 2021 | 65 | 0.050 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 40 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2022 | 183 | 0.050 |
Why?
|
| Organoids | 1 | 2020 | 42 | 0.050 |
Why?
|
| Thyroid Neoplasms | 2 | 1999 | 68 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 2 | 1999 | 2 | 0.050 |
Why?
|
| Vomiting | 1 | 2021 | 56 | 0.050 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 2 | 0.050 |
Why?
|
| Multiprotein Complexes | 1 | 2020 | 56 | 0.050 |
Why?
|
| Drainage | 1 | 2021 | 133 | 0.050 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2020 | 10 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 18 | 0.040 |
Why?
|
| Mutation | 2 | 2014 | 1213 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 230 | 0.040 |
Why?
|
| Trypsin | 1 | 2020 | 64 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 111 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 1420 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 280 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 188 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2022 | 307 | 0.040 |
Why?
|
| Disinfection | 1 | 2020 | 112 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 164 | 0.040 |
Why?
|
| Binding Sites | 1 | 2020 | 631 | 0.040 |
Why?
|
| Informed Consent | 1 | 2020 | 127 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 737 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2016 | 3187 | 0.040 |
Why?
|
| Catheterization | 1 | 2019 | 209 | 0.040 |
Why?
|
| Osteocalcin | 1 | 2018 | 37 | 0.040 |
Why?
|
| Retinol-Binding Proteins | 1 | 2018 | 28 | 0.040 |
Why?
|
| Prealbumin | 1 | 2018 | 25 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 4655 | 0.040 |
Why?
|
| Cardiac Catheterization | 1 | 2001 | 419 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 249 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 88 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2022 | 753 | 0.040 |
Why?
|
| Protein Binding | 1 | 2020 | 1027 | 0.040 |
Why?
|
| Gene Expression | 2 | 2017 | 770 | 0.040 |
Why?
|
| Vitamins | 1 | 2018 | 134 | 0.040 |
Why?
|
| Observer Variation | 1 | 2018 | 330 | 0.040 |
Why?
|
| Utah | 1 | 2017 | 27 | 0.040 |
Why?
|
| Boston | 1 | 2017 | 35 | 0.040 |
Why?
|
| Critical Care | 1 | 2020 | 263 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 211 | 0.040 |
Why?
|
| Pancreatic Function Tests | 1 | 2017 | 6 | 0.040 |
Why?
|
| Risk | 2 | 2013 | 563 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2017 | 53 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 95 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2017 | 61 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 849 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 90 | 0.040 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1997 | 46 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 371 | 0.040 |
Why?
|
| Microarray Analysis | 1 | 2017 | 63 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 238 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 700 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 1997 | 138 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 129 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 1996 | 44 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 125 | 0.030 |
Why?
|
| Atrophy | 1 | 2016 | 112 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 349 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 1997 | 87 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1996 | 100 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 104 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 28 | 0.030 |
Why?
|
| Efficiency | 1 | 2016 | 49 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 492 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 109 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 955 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 369 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1745 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 236 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 332 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 83 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2017 | 193 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 48 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 786 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 521 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 562 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 792 | 0.030 |
Why?
|
| Publishing | 1 | 2016 | 89 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 502 | 0.030 |
Why?
|
| Phenotype | 2 | 2014 | 947 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 57 | 0.030 |
Why?
|
| Mice | 3 | 2015 | 8474 | 0.030 |
Why?
|
| Fish Oils | 1 | 1994 | 21 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 241 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 170 | 0.030 |
Why?
|
| Peptide Library | 1 | 2014 | 16 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 311 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
| Chlorides | 1 | 2014 | 68 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1174 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1996 | 411 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 57 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 294 | 0.030 |
Why?
|
| Reproduction | 1 | 2014 | 48 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 103 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2014 | 58 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2014 | 91 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 2689 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 33 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 52 | 0.030 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2013 | 34 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 622 | 0.030 |
Why?
|
| Lipoma | 1 | 2013 | 24 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 145 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 109 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2013 | 58 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 51 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 326 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 82 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2013 | 238 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 630 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 196 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 411 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 529 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2014 | 447 | 0.030 |
Why?
|
| Fibrosis | 1 | 2014 | 371 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 2011 | 27 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 206 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 434 | 0.020 |
Why?
|
| Sphincter of Oddi Dysfunction | 1 | 2012 | 48 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 215 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 383 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2011 | 159 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 299 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 223 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2013 | 400 | 0.020 |
Why?
|
| Animals | 3 | 2015 | 20881 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 880 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 331 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 375 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1070 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2550 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1641 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 1173 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2223 | 0.010 |
Why?
|
| India | 1 | 2001 | 41 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2001 | 48 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2001 | 112 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2324 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 1999 | 1 | 0.010 |
Why?
|
| Calcitonin | 1 | 1999 | 21 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1999 | 31 | 0.010 |
Why?
|
| Neck Dissection | 1 | 1999 | 55 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2001 | 373 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 511 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 1996 | 3 | 0.010 |
Why?
|
| Codon | 1 | 1996 | 21 | 0.010 |
Why?
|
| Hirschsprung Disease | 1 | 1996 | 4 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1996 | 22 | 0.010 |
Why?
|
| Hyperparathyroidism | 1 | 1996 | 40 | 0.010 |
Why?
|
| Cysteine | 1 | 1996 | 112 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1997 | 329 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 1997 | 1033 | 0.010 |
Why?
|
| Insulin | 1 | 1997 | 619 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1997 | 514 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1997 | 597 | 0.010 |
Why?
|
| Cell Line | 1 | 1997 | 1752 | 0.010 |
Why?
|